8-K: NewAmsterdam Pharma Reports Positive Full Year 2024 Financial Results and Highlights Clinical Progress

NewAmsterdam Pharma announces full year 2024 financial results, highlighting a strong cash position and progress in clinical development of obicetrapib.

Summary

• NewAmsterdam Pharma reported its full year 2024 financial results and provided a corporate update on February 26, 2025.
• The company has $834.2 million in cash, cash equivalents, and marketable securities as of December 31, 2024.
• Revenue for the year ended December 31, 2024, was $45.6 million, compared to $14.1 million in the previous year.
• Research and Development expenses were $151.4 million for the year ended December 31, 2024, compared to $159.4 million in the year ended December 31, 2023.
• Selling, General and Administrative expenses were $70.4 million for the year ended December 31, 2024, compared to $37.6 million in the year ended December 31, 2023.
• The net loss for the year ended December 31, 2024, was $241.6 million, compared to a net loss of $176.9 million in the year ended December 31, 2023.
• The company is developing obicetrapib as a treatment for cardiovascular disease.
• EMA submission is expected in the second half of 2025 by partner Menarini.
• Additional data from BROADWAY, BROOKLYN, and TANDEM trials will be presented throughout 2025.
• The Phase 3 PREVAIL CVOT trial remains on track.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, promising clinical trial data, and a clear path forward for obicetrapib. The company's strong cash position and progress in clinical development contribute to a favorable sentiment.

Positives

• The company has a strong cash position of $834.2 million.
• Revenue increased significantly from $14.1 million to $45.6 million year-over-year.
• Multiple Phase 3 trials (BROADWAY, TANDEM, BROOKLYN) showed positive topline results with statistically significant LDL-C reductions.
• A new patent was issued for obicetrapib, extending intellectual property protection until July 2043.
• Enrollment was completed in the PREVAIL CVOT trial with over 9,500 patients.
• The company is increasing focus and efforts around launch readiness with plans to scale up and build inventory and commercial capabilities sufficient to support the launch of obicetrapib in both the U.S. and Europe, if approved.

Negatives

• The company experienced a net loss of $241.6 million for the year ended December 31, 2024, which is higher than the $176.9 million loss in the previous year.
• Selling, General and Administrative expenses increased significantly from $37.6 million to $70.4 million year-over-year.

Risks

• The success of obicetrapib is dependent on regulatory approvals.
• The company faces competition from other pharmaceutical companies developing treatments for cardiovascular disease.
• Clinical trial results may not be indicative of future results or real-world outcomes.
• Global economic and political conditions, including the Russia-Ukraine and Israel-Hamas conflicts, could impact the business.

Future Outlook

The company anticipates sharing additional data from Phase 3 trials, advancing regulatory interactions, and scaling up commercial capabilities in preparation for the potential launch of obicetrapib.

Management Comments

• 2024 was a transformative year for NewAmsterdam, marked by compelling data from three pivotal Phase 3 trials BROOKLYN, TANDEM, and BROADWAY where we observed durable LDL-C lowering by obicetrapib for CVD patients.
• In 2025, we look forward to sharing additional data and insights from these trials, including the impact of obicetrapib on the exploratory endpoint of major adverse cardiac events (MACE), at leading medical meetings and journal publications, as well as advancing regulatory interactions, including an anticipated EMA submission in the second half by our partner Menarini.
• Following our successful $479 million upsized financing in December, we have the necessary capital to fund operations beyond the PREVAIL cardiovascular outcomes trial (CVOT) readout and commercial launch of obicetrapib in the U.S., pending regulatory approval.
• We are excited to build on the strong momentum from the past year, as we work diligently to deliver a potentially transformative therapy to millions of CVD patients globally.

Industry Context

NewAmsterdam Pharma is operating in the cardiovascular disease treatment market, which has a significant unmet need for more effective and well-tolerated LDL-lowering therapies. The company's focus on obicetrapib, a CETP inhibitor, positions it to potentially address this need and compete with existing statin and non-statin therapies.

Comparison to Industry Standards

• The reported LDL-C reductions in the BROADWAY, TANDEM, and BROOKLYN trials are competitive with other LDL-lowering therapies.
• For example, PCSK9 inhibitors like Amgen's Repatha and Sanofi/Regeneron's Praluent have demonstrated significant LDL-C reductions, but require injections.
• NewAmsterdam's oral obicetrapib offers a potentially more convenient option for patients.
• The company's cash position of $834.2 million provides a strong financial foundation compared to other clinical-stage biopharmaceutical companies.
• The PREVAIL CVOT trial, with over 9,500 patients enrolled, is a large-scale study comparable to other cardiovascular outcomes trials conducted by major pharmaceutical companies.

Stakeholder Impact

• Shareholders: Positive results and strong financial position could lead to increased shareholder value.
• Patients: Successful development and approval of obicetrapib could provide a new treatment option for cardiovascular disease.
• Employees: Company growth and expansion could create new job opportunities.
• Partners: Collaboration with Menarini for European commercialization.

Next Steps

• Presenting additional data from BROADWAY, BROOKLYN, and TANDEM trials throughout 2025.
• Advancing regulatory interactions, including an anticipated EMA submission in the second half of 2025 by partner Menarini.
• Continuing the Phase 3 PREVAIL CVOT trial.
• Continuing the VINCENT Phase 2 trial.
• Continuing the REMBRANDT Phase 3 trial.
• Scaling up and building inventory and commercial capabilities to support the launch of obicetrapib in both the U.S. and Europe, if approved.

Key Dates